Loading company…
Shanghai Enkai Cell Technology develops NK cell-based therapies and products for major clinical diseases.
Founded in 2020, Shanghai Enkai Cell Technology is based in Shanghai, China, and develops cell drugs based on natural killer (NK) cells. Its ABCDE-NK® platform includes technologies and products across four categories and twelve series. The company raised Series A++ funding in November 2024 and nearly CNY 100 million in Series A+++ funding in July 2025 from Pudong Capital and Zhongke Xianjin Fund.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in